Physician profile
Blake Fenkell
NPI 1033596069
$34,522.19
in general payments reported to CMS, 2019-2025
15 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,863 · 2020: $20K · 2021: $7,593 · 2022: $2,521 · 2023: $39.80 · 2024: $50.20 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $25,028.42 | 2020-2021 | |
| Pinnacle, INC | $4,310.55 | 2019-2025 | |
| Medical Device Business Services, INC. | $1,800.00 | 2019 | |
| Elite Orthopedics, LLC | $1,319.32 | 2021 | |
| Zimmer Biomet Holdings, INC. | $626.56 | 2019-2023 | Trabecular Metal, Persona, Arcos |
| Stryker Corporation | $499.47 | 2019-2025 | Pangea |
| Baxter Healthcare | $278.25 | 2019 | |
| Depuy Synthes Sales INC. | $209.84 | 2019-2025 | Na, Va-Lcp |
| Smith+Nephew, INC. | $173.67 | 2019-2022 | |
| Medtronic USA, INC. | $123.35 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $56.10 | 2024-2025 | Zilretta, Exparel, Iovera |
| Fidia Pharma USA INC. | $36.88 | 2023-2024 | Hyalgan |
| Horizon Therapeutics Plc | $27.16 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $21.28 | 2025 | |
| Anika Therapeutics, INC. | $11.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Fenkell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.